Vanda Pharmaceuticals stock’s explosive rally may be more hype than substance
Vanda Pharmaceuticals (NASDAQ: VNDA) opened some 45% higher today after the biotech firm said it has received the FDA’s approval for its treatment of schizophrenia and bipolar I disorder. The BYSANTI (milsaperidone) announcement is a welcome reprieve for VNDA that’s been under pressure this year as investors weighed “disappointing” Q4 earnings against a backdrop of
